Sparks commentary

Consumer

Sparks

Dr Martens (LSE: DOCS) – H125 results in line with expectations
Published by Russell Pointon

H125 was a tough period for Dr Martens, with a constant currency revenue decline of 16% (versus guidance of a 20% decline) and an adjusted EBIT loss of £4.3m versus a profit of c £40m in H124. FY25 is viewed as a year of transition and guidance is unchanged, which includes US direct to consumer returning to growth in H225 and US wholesale revenue declining by double digits for the year. Management points to encouraging trading, with all thee regions positive, albeit the peak weeks of trading are ahead. It has also indicated that its cost savings plan will deliver savings of £25m, at the top end of prior expectations.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.